• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    2/15/23 8:12:24 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13G/A 1 tm236297d4_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    I-MAB

    (Name of Issuer)

     

    Ordinary Shares, par value US$0.0001**

    American Depositary Shares

    (Title of Class of Securities)

     

    44975P103**

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨        Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    x       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 2 of 16 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    IBC Investment Seven Limited

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Hong Kong

     

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    3,641,554 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    3,641,554 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,641,554 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.9% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

    (1) Represents 3,641,554 ordinary shares (including 3,641,544 ordinary shares represented by 1,583,280 American Depositary Shares (“ADSs”), each ten (10) ADSs representing twenty-three (23) ordinary shares) held by IBC Investment Seven Limited. 

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 3 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    CBC SPVII LIMITED

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Hong Kong SAR

     

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    5,574,560 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    5,574,560 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,574,560 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.9% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

    (1) Represents 5,574,560 ordinary shares (including 5,574,556 ordinary shares represented by 2,423,720 ADSs) held by CBC SPVII LIMITED.

    (2)  Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 4 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    CBC Investment I-Mab Limited

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Virgin Islands

     

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    11,784,164 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    11,784,164 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,784,164 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.2% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

    (1) Represents 11,784,164 ordinary shares (including 11,784,142 ordinary shares represented by 5,123,540 ADSs) held by CBC Investment I-Mab Limited.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 5 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    C-Bridge II Investment Ten Limited

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Virgin Islands

     

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    2,369,546 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    2,369,546 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,369,546 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.2% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

     

    (1) Represents 2,369,546 ordinary shares (including 2,369,529 ordinary shares represented by 1,030,230 ADSs) held by C-Bridge II Investment Ten Limited.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

    CUSIP No. 44975P103

     

    SCHEDULE 13G Page 6 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    Everest Medicines Limited

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    6,078,571

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    6,078,571

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,078,571

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.2% (1)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

    (1) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

      

    CUSIP No. 44975P103

     

    SCHEDULE 13G Page 7 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    C-Bridge Healthcare Fund II, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    14,153,710 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    14,153,710 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,153,710 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.4% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    PN

     

           

     

    (1) Represents 11,784,164 ordinary shares (including 11,784,142 ordinary shares represented by 5,123,540 ADSs) held by CBC Investment I-Mab Limited and 2,369,546 ordinary shares (including 2,369,529 ordinary shares represented by 1,030,230 ADSs) held by C-Bridge II Investment Ten Limited.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103

     

    SCHEDULE 13G Page 8 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    C-Bridge Healthcare Fund GP II, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    14,153,710 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    14,153,710 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,153,710 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.4% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    PN

     

           

     

    (1) Represents 11,784,164 ordinary shares (including 11,784,142 ordinary shares represented by 5,123,540 ADSs) held by CBC Investment I-Mab Limited and 2,369,546 ordinary shares (including 2,369,529 ordinary shares represented by 1,030,230 ADSs) held by C-Bridge II Investment Ten Limited.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer). 

     

     

     

     

    CUSIP No. 44975P103

     

    SCHEDULE 13G Page 9 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    C-Bridge Capital GP, Ltd.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    23,369,824 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    23,369,824 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    23,369,824 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.2% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

           

     

    (1) Represents 11,784,164 ordinary shares (including 11,784,142 ordinary shares represented by 5,123,540 ADSs) held by CBC Investment I-Mab Limited, 2,369,546 ordinary shares (including 2,369,529 ordinary shares represented by 1,030,230 ADSs) held by C-Bridge II Investment Ten Limited, 3,641,554 ordinary shares (including 3,641,544 represented by 1,583,280 ADSs) held by IBC Investment Seven Limited and 5,574,560 ordinary shares (including 5,574,556 ordinary shares represented by 2,423,720 ADSs) held by CBC SPVII LIMITED.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 10 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    I-Bridge Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    9,216,114 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    9,216,114 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,216,114 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.8% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

    (1) Represents 3,641,554 ordinary shares (including 3,641,544 represented by 1,583,280 ADSs) held by IBC Investment Seven Limited and 5,574,560 ordinary shares (including 5,574,556 ordinary shares represented by 2,423,720 ADSs) held by CBC SPVII LIMITED.

    (2)  Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 11 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    I-Bridge Healthcare GP, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    9,216,114 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    9,216,114 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,216,114 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.8% (2)

     

    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

    (1) Represents 3,641,554 ordinary shares (including 3,641,544 represented by 1,583,280 ADSs) held by IBC Investment Seven Limited and 5,574,560 ordinary shares (including 5,574,556 ordinary shares represented by 2,423,720 ADSs) held by CBC SPVII LIMITED.

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 12 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    I-Bridge Capital GP, Ltd.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    9,216,114 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    9,216,114 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,216,114 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.8%(2)

     

    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

    (1) Represents 3,641,554 ordinary shares (including 3,641,544 represented by 1,583,280 ADSs) held by IBC Investment Seven Limited and 5,574,560 ordinary shares (including 5,574,556 ordinary shares represented by 2,423,720 ADSs) held by CBC SPVII LIMITED. 

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 13 of 16 Pages

     


    1

    NAMES OF REPORTING PERSONS

     

    Wei Fu

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Singapore

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

     

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    29,448,395 (1)

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    29,448,395 (1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    29,448,395 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.4%(2)

     

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

    (1) Represents 29,448,395 ordinary shares (including 23,369,771 ordinary shares represented by 10,160,770 ADSs) held by other reporting persons

    (2) Based on 190,879,919 ordinary shares outstanding as of December 31, 2022 (excluding 2,961,319 ordinary shares issued to the depositary bank of the Issuer for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of the Issuer).

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 14 of 16 Pages

     

    Item 1(a)Name of Issuer:

     

    I-MAB (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    55th – 56th Floor, New Bund Center

    555 West Haiyang Road, Pudong District

    Shanghai, 200124

    People’s Republic of China

     

    Item 2(a)Name of Persons Filing:

     

    This Amendment No.2 to the Schedule 13G is filed by and on behalf of:

     

    1.IBC Investment Seven Limited

     

    2.CBC SPVII LIMITED

     

    3.CBC Investment I-Mab Limited

     

    4.C-Bridge II Investment Ten Limited

     

    5.Everest Medicines Limited

      

    6.C-Bridge Healthcare Fund II, L.P.

     

    7.C-Bridge Healthcare Fund GP II, L.P.

     

    8.C-Bridge Capital GP, Ltd.

     

    9.I-Bridge Healthcare Fund, L.P.

     

    10.I-Bridge Healthcare GP, L.P.

     

    11.I-Bridge Capital GP, Ltd.
       
     12.

    Wei Fu 

     

    This statement on Schedule 13G relates to securities directly held by IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited and Everest Medicines Limited.

     

    CBC Investment I-Mab Limited and C-Bridge II Investment Ten Limited are controlled by C-Bridge Healthcare Fund II, L.P., whose general partner is C-Bridge Healthcare Fund GP II, L.P., and its general partner is C-Bridge Capital GP, Ltd.

     

    CBC SPVII Limited and IBC Investment Seven Limited are controlled by I-Bridge Healthcare Fund, L.P., whose general partner is I-Bridge Healthcare GP, L.P., and its general partner is I-Bridge Capital GP, Ltd., which is indirectly controlled by C-Bridge Capital GP, Ltd.

     

    Mr. Wei Fu is the sole director of C-Bridge Capital GP, Ltd.

     

    Everest Medicines Limited is a public company listed on the Hong Kong Stock Exchange and controlled by funds which are under common control of the C-Bridge group, which, in turn, is controlled by Mr. Wei Fu.

     

    C-Bridge Healthcare Fund II, L.P., C-Bridge Healthcare Fund GP II, L.P., C-Bridge Capital GP, Ltd., I-Bridge Healthcare Fund, L.P., I-Bridge Healthcare GP, L.P., I-Bridge Capital GP, Ltd., and Mr. Wei Fu may be deemed to beneficially own the securities of the Issuer owned by the entities which they control.

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 15 of 16 Pages

     

     

    Item 2(b)Address of Principal Business Office or, If None, Residence

     

    The business address of each reporting person is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

     

    Item 2(c)Citizenship

     

    1.IBC Investment Seven Limited: Hong Kong SAR

     

    2.CBC SPVII LIMITED: Hong Kong SAR

     

    3.CBC Investment I-Mab Limited: British Virgin Islands

     

    4.C-Bridge II Investment Ten Limited: British Virgin Islands

     

    5.Everest Medicines Limited: Cayman Islands

     

    6.C-Bridge Healthcare Fund II, L.P.: Cayman Islands

     

    7.C-Bridge Healthcare Fund GP II, L.P.: Cayman Islands

     

    8.C-Bridge Capital GP, Ltd.: Cayman Islands

     

    9.I-Bridge Healthcare Fund, L.P.: Cayman Islands

     

    10.I-Bridge Healthcare GP, L.P.: Cayman Islands

     

    11.I-Bridge Capital GP, Ltd.: Cayman Islands
       
     12.

    Wei Fu: Singapore 

      

    Item 2(d)Title of Class of Securities:

     

    Ordinary Shares, par value US$0.0001

     

    Item 2(e)CUSIP Number:

     

    44975P103 

     

    Item 3.Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

     

    Not applicable.

     

    Item 4.Ownership

     

    The information for each reporting person contained in rows 5-11 of the cover pages and Item 2(a) is incorporated herein by reference. 

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not applicable. 

     

     

     

     

    CUSIP No. 44975P103 

     

    SCHEDULE 13G Page 16 of 16 Pages

     

    Item 7.Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    The members of this group are set forth as reporting persons on this Schedule 13G.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications

     

    Not applicable.

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 15, 2023

     

     

      IBC Investment Seven Limited
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      CBC SPVII LIMITED
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      CBC Investment I-Mab Limited
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      C-Bridge II Investment Ten Limited
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      Everest Medicines Limited
       
      By: /s/ Xiaofan Zhang
      Name: Xiaofan ZHANG
      Title: Director

     

     

     

     

      C-Bridge Healthcare Fund II, L.P.
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Authorized Representative

     

      C-Bridge Healthcare Fund GP II, L.P.
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Authorized Representative

     

      C-Bridge Capital GP, Ltd.
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      I-Bridge Healthcare Fund, L.P.
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Authorized Representative

     

      I-Bridge Healthcare GP, L.P.
       
      By: /s/ Wei Fu
      Name: Wei FU
      Title: Authorized Representative

     

      I-Bridge Capital GP, Ltd.
       
      By:  /s/ Wei Fu
      Name: Wei FU
      Title: Director

     

      Wei FU
       
      By: /s/ Wei Fu

     

     

     

    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form F-3 filed by I-MAB

      F-3 - I-Mab (0001778016) (Filer)

      5/2/25 5:01:56 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/30/25 7:14:42 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/4/25 4:59:51 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    See more

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

      Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

      1/6/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Third Quarter 2024 Results

      Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

      11/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/13/24 11:26:50 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/9/24 4:01:20 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by I-MAB

      SC 13D - I-Mab (0001778016) (Subject)

      12/1/23 2:41:06 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

      ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain. "We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more information becomes available fr

      4/30/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

      ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

      3/26/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care